T1	CHEM 69 80	vedolizumab
#1	AnnotatorNotes T1	C2742797; vedolizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T2	CHEM 106 116	adalimumab
#2	AnnotatorNotes T2	C1122087; adalimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T3	DISO 135 151	colitis ulcerosa
#3	AnnotatorNotes T3	C0009324; Ulcerative Colitis; Disease or Syndrome
T4	PROC 173 254	Estudio multicéntrico, aleatorizado, doble ciego, de doble simulación, controlado
T5	CHEM 259 275	principio activo
#4	AnnotatorNotes T5	C1372955; Active ingredient; Chemical Viewed Functionally
T6	PROC 281 315	evaluar la eficacia y la seguridad
#5	AnnotatorNotes T6	C0511730; Identify product efficacy and safety issues; Health Care Activity
T7	CHEM 320 331	vedolizumab
#6	AnnotatorNotes T7	C2742797; vedolizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T8	CHEM 357 367	adalimumab
#7	AnnotatorNotes T8	C1122087; adalimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T9	DISO 386 402	colitis ulcerosa
#8	AnnotatorNotes T9	C0009324; Ulcerative Colitis; Disease or Syndrome
T10	DISO 425 441	Colitis Ulcerosa
#9	AnnotatorNotes T10	C0009324; Ulcerative Colitis; Disease or Syndrome
T11	PROC 490 501	diagnóstico
#10	AnnotatorNotes T11	C0011900; Diagnosis; Diagnostic Procedure
T12	DISO 505 507	CU
#11	AnnotatorNotes T12	C0009324; Ulcerative Colitis; Disease or Syndrome
T13	PROC 996 1003	tratado
#12	AnnotatorNotes T13	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T14	PROC 608 619	endoscópica
#13	AnnotatorNotes T14	C0014245; Endoscopy (procedure); Diagnostic Procedure
T15	DISO 685 687	CU
#14	AnnotatorNotes T15	C0009324; Ulcerative Colitis; Disease or Syndrome
T16	PROC 809 820	endoscópica
#15	AnnotatorNotes T16	C0014245; Endoscopy (procedure); Diagnostic Procedure
T17	PROC 853 867	aleatorización
#16	AnnotatorNotes T17	C0034656; Randomization; Research Activity
T18	DISO 900 902	CU
#17	AnnotatorNotes T18	C0009324; Ulcerative Colitis; Disease or Syndrome
T19	ANAT 942 947	recto
#18	AnnotatorNotes T19	C0034896; Rectum; Body Part, Organ, or Organ Component | C1278926; Entire rectum; Body Part, Organ, or Organ Component
T20	ANAT 960 965	colon
#19	AnnotatorNotes T20	C0009368; Colon structure; Body Part, Organ, or Organ Component | C1281569; Entire colon; Body Part, Organ, or Organ Component
T21	PROC 1149 1156	tratado
#20	AnnotatorNotes T21	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T22	PROC 1114 1125	tratamiento
#21	AnnotatorNotes T22	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T23	PROC 1219 1243	tratamiento convencional
#22	AnnotatorNotes T23	C2945704; Conventional Treatment; Therapeutic or Preventive Procedure
T24	PROC 1309 1327	resección colónica
T25	PROC 1340 1367	colectomía subtotal o total
T26	DISO 1409 1418	infección
#23	AnnotatorNotes T26	C0009450; Communicable Diseases; Disease or Syndrome | C3714514; Infection; Pathologic Function
T27	DISO 1510 1550	leucoencefalopatía multifocal progresiva
#24	AnnotatorNotes T27	C0023524; Leukoencephalopathy, Progressive Multifocal; Disease or Syndrome
T28	CHEM 1670 1680	biosimilar
#25	AnnotatorNotes T28	C4045974; Biosimilars; Pharmacologic Substance
T29	DISO 1552 1555	LMP
#26	AnnotatorNotes T29	C0023524; Leukoencephalopathy, Progressive Multifocal; Disease or Syndrome
T30	CHEM 1597 1604	fármaco
#27	AnnotatorNotes T30	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T31	CHEM 1651 1667	agente biológico
#28	AnnotatorNotes T31	C0005515; Biological Factors; Biologically Active Substance
T32	CHEM 1831 1842	vedolizumab
#29	AnnotatorNotes T32	C2742797; vedolizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T33	CHEM 1844 1855	natalizumab
#30	AnnotatorNotes T33	C1172734; natalizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T34	CHEM 1857 1867	efalizumab
#31	AnnotatorNotes T34	C1174995; efalizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T35	CHEM 1869 1879	adalimumab
#32	AnnotatorNotes T35	C1122087; adalimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T36	CHEM 1882 1891	rituximab
#33	AnnotatorNotes T36	C0393022; rituximab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T37	CHEM 1020 1068	antagonistas del factor de necrosis tumoral alfa
T38	CHEM 1070 1075	TNF-α
T39	CHEM 1175 1196	antagonistas de TNF-α
T40	ANAT 1319 1327	colónica
#34	AnnotatorNotes T40	C0009368; Colon structure; Body Part, Organ, or Organ Component | C1281569; Entire colon; Body Part, Organ, or Organ Component
T41	PROC 1578 1604	administración del fármaco
#35	AnnotatorNotes T41	C3469597; Administration of medication; Therapeutic or Preventive Procedure
T42	Date 12 16	2015
T43	Route 81 83	IV
#36	AnnotatorNotes T43	C1522726; Intravenous Route of Drug Administration; Functional Concept
T44	Route 117 119	SC
T45	LIVB 123 130	sujetos
#37	AnnotatorNotes T45	C0681850; Study Subject; Group
T46	Route 332 334	IV
#38	AnnotatorNotes T46	C1522726; Intravenous Route of Drug Administration; Functional Concept
T47	Route 368 370	SC
T48	LIVB 374 381	sujetos
#39	AnnotatorNotes T48	C0681850; Study Subject; Group
T49	LIVB 471 477	sujeto
#40	AnnotatorNotes T49	C0681850; Study Subject; Group
T50	Duration 520 536	al menos 6 meses
T51	LIVB 669 675	sujeto
#41	AnnotatorNotes T51	C0681850; Study Subject; Group
T52	Duration 828 839	los 14 días
T53	LIVB 872 878	sujeto
#42	AnnotatorNotes T53	C0681850; Study Subject; Group
T54	Spec_cue 888 899	indicios de
T56	LIVB 981 987	sujeto
#43	AnnotatorNotes T56	C0681850; Study Subject; Group
T58	LIVB 1131 1137	sujeto
#44	AnnotatorNotes T58	C0681850; Study Subject; Group
T59	Neg_cue 1138 1140	no
T60	Date 1244 1250	actual
T61	LIVB 1281 1287	sujeto
#45	AnnotatorNotes T61	C0681850; Study Subject; Group
T62	LIVB 1372 1378	sujeto
#46	AnnotatorNotes T62	C0681850; Study Subject; Group
T63	Spec_cue 1398 1408	indicio de
T64	LIVB 1452 1458	sujeto
#47	AnnotatorNotes T64	C0681850; Study Subject; Group
T65	LIVB 1622 1628	sujeto
#48	AnnotatorNotes T65	C0681850; Study Subject; Group
T66	Duration 1712 1723	los 60 días
T67	Duration 1726 1737	5 semividas
T68	LIVB 1788 1794	sujeto
#49	AnnotatorNotes T68	C0681850; Study Subject; Group
T55	PROC 649 664	histopatológico
#50	AnnotatorNotes T55	C0430445; Histopathology test; Laboratory Procedure
A1	Assertion T18 Speculated
A2	Assertion T21 Negated
A3	Assertion T26 Speculated
A4	Status T13 History_of
A5	Status T37 History_of
A6	Status T38 History_of
A7	Status T21 History_of
A8	Status T39 History_of
A9	Assertion T39 Negated
A10	Status T31 History_of
A11	Status T28 History_of
A12	Status T32 History_of
A13	Status T33 History_of
A14	Status T34 History_of
A15	Status T35 History_of
A16	Status T36 History_of
#51	AnnotatorNotes T44	C1522438; Subcutaneous Route of Drug Administration; Functional Concept
#52	AnnotatorNotes T47	C1522438; Subcutaneous Route of Drug Administration; Functional Concept
#53	AnnotatorNotes T60	C0521116; Current (present time); Temporal Concept 
#54	AnnotatorNotes T37	C1562242; Anti-tumor necrosis factor alpha drug (product); Immunologic Factor · Pharmacologic Substance
#55	AnnotatorNotes T38	C1562242; Anti-tumor necrosis factor alpha drug (product); Immunologic Factor · Pharmacologic Substance
#56	AnnotatorNotes T39	C1562242; Anti-tumor necrosis factor alpha drug (product); Immunologic Factor · Pharmacologic Substance
#57	AnnotatorNotes T25	C0149750; Partial resection of colon; Therapeutic or Preventive Procedure + C0192871; Total colectomy; Therapeutic or Preventive Procedure
#58	AnnotatorNotes T24	C4763870; Colon Resection; Therapeutic or Preventive Procedure 
T57	Neg_cue 1077 1080	sin
T69	Observation 1081 1098	respuesta clínica
A17	Assertion T69 Negated
#59	AnnotatorNotes T69	C4055223; Clinical Response; Finding
R1	Negation Arg1:T57 Arg2:T69	
R2	Negation Arg1:T59 Arg2:T21	
R3	Negation Arg1:T59 Arg2:T39	
R4	Used_for Arg1:T39 Arg2:T21	
R5	Speculation Arg1:T63 Arg2:T26	
T70	Quantifier_or_Qualifier 1419 1425	activa
A18	Assertion T70 Speculated
#60	AnnotatorNotes T70	C0679217; Active State; Idea or Concept
R6	Has_Quantifier_or_Qualifier Arg1:T26 Arg2:T70	
R7	Speculation Arg1:T63 Arg2:T70	
R8	Has_Route_or_Mode Arg1:T1 Arg2:T43	
R9	Has_Route_or_Mode Arg1:T2 Arg2:T44	
R10	Experiences Arg1:T45 Arg2:T1	
R11	Experiences Arg1:T45 Arg2:T2	
R12	Experiences Arg1:T45 Arg2:T3	
R13	Has_Route_or_Mode Arg1:T7 Arg2:T46	
R14	Has_Route_or_Mode Arg1:T8 Arg2:T47	
R15	Experiences Arg1:T48 Arg2:T7	
R16	Experiences Arg1:T48 Arg2:T8	
R17	Experiences Arg1:T48 Arg2:T5	
R18	Experiences Arg1:T48 Arg2:T9	
R19	Experiences Arg1:T49 Arg2:T12	
T71	PROC 549 560	inscripción
#61	AnnotatorNotes T71	C4041024; Enrollment in clinical trial; Research Activity
R20	Before Arg1:T11 Arg2:T71	
R21	Has_Duration_or_Interval Arg1:T12 Arg2:T50	
T72	Quantifier_or_Qualifier 508 519	establecido
#62	AnnotatorNotes T72	C0443211; Established; Qualitative Concept
R22	Has_Quantifier_or_Qualifier Arg1:T12 Arg2:T72	
R24	Before Arg1:T14 Arg2:T11	
R25	Before Arg1:T55 Arg2:T11	
T73	CONC 588 605	evidencia clínica
#63	AnnotatorNotes T73	C5554846; Clinical Evidence; Idea or Concept
R27	Experiences Arg1:T49 Arg2:T14	
R28	Experiences Arg1:T49 Arg2:T55	
R29	Experiences Arg1:T51 Arg2:T15	
T74	Quantifier_or_Qualifier 691 712	moderada a gravemente
#64	AnnotatorNotes T74	C1299393; Moderate to severe; Qualitative Concept
R30	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T74	
T75	Quantifier_or_Qualifier 713 719	activa
#65	AnnotatorNotes T75	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R31	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T75	
T76	CONC 752 767	puntuación Mayo
#66	AnnotatorNotes T76	C5420651; Ulcerative Colitis Disease Activity Index; Intellectual Product
T77	Result_or_Value 780 786	6 a 12
R32	Has_Result_or_Value Arg1:T76 Arg2:T77	
T78	Result_or_Value 821 824	≥ 2
T79	CONC 795 820	subpuntuación endoscópica
R33	Has_Result_or_Value Arg1:T79 Arg2:T78	
R34	Experiences Arg1:T51 Arg2:T16	
R35	Before Arg1:T16 Arg2:T17	
R36	Overlap Arg1:T16 Arg2:T52	
R37	Overlap Arg1:T79 Arg2:T52	
R38	Speculation Arg1:T54 Arg2:T18	
R39	Experiences Arg1:T53 Arg2:T18	
T80	Quantifier_or_Qualifier 903 947	que se extiende en sentido proximal al recto
R40	Location_of Arg1:T19 Arg2:T18	
T81	Result_or_Value 949 956	≥ 15 cm
R41	Location_of Arg1:T20 Arg2:T18	
T82	Observation 960 975	colon afectados
R43	Has_Result_or_Value Arg1:T82 Arg2:T81	
R42	Experiences Arg1:T56 Arg2:T13	
R44	Used_for Arg1:T37 Arg2:T13	
R45	Used_for Arg1:T38 Arg2:T13	
R46	Overlap Arg1:T13 Arg2:T69	
R47	Overlap Arg1:T69 Arg2:T22	
R48	Experiences Arg1:T56 Arg2:T22	
A19	Status T22 History_of
R49	Experiences Arg1:T58 Arg2:T13	
R50	Experiences Arg1:T58 Arg2:T69	
R51	Experiences Arg1:T58 Arg2:T22	
R52	Experiences Arg1:T58 Arg2:T21	
R53	Experiences Arg1:T58 Arg2:T23	
R54	Overlap Arg1:T23 Arg2:T60	
T83	Observation 1207 1215	fallando
R55	Overlap Arg1:T83 Arg2:T23	
R56	Experiences Arg1:T56 Arg2:T83	
R57	Experiences Arg1:T56 Arg2:T21	
R58	Experiences Arg1:T58 Arg2:T83	
R59	Experiences Arg1:T56 Arg2:T23	
R60	Location_of Arg1:T40 Arg2:T24	
R61	Experiences Arg1:T61 Arg2:T24	
R62	Experiences Arg1:T61 Arg2:T25	
T84	Quantifier_or_Qualifier 1328 1335	extensa
#67	AnnotatorNotes T84	C0231449; Extended; Spatial Concept
R63	Has_Quantifier_or_Qualifier Arg1:T24 Arg2:T84	
R64	Experiences Arg1:T62 Arg2:T26	
T85	PROC 1437 1446	selección
#68	AnnotatorNotes T85	C0242802; Patient Selection; Research Activity
R65	Overlap Arg1:T26 Arg2:T85	
R66	Experiences Arg1:T64 Arg2:T27	
R67	Experiences Arg1:T64 Arg2:T29	
T86	CONC 1472 1556	lista de verificación subjetiva de la leucoencefalopatía multifocal progresiva (LMP)
T87	Result_or_Value 1557 1565	positiva
#69	AnnotatorNotes T87	C1446409; Positive; Finding
R68	Has_Quantifier_or_Qualifier Arg1:T86 Arg2:T87	
R69	Before Arg1:T87 Arg2:T41	
R70	Used_for Arg1:T30 Arg2:T41	
R71	Experiences Arg1:T64 Arg2:T41	
R72	Experiences Arg1:T65 Arg2:T31	
R73	Experiences Arg1:T65 Arg2:T28	
R74	Overlap Arg1:T31 Arg2:T66	
R75	Has_Duration_or_Interval Arg1:T31 Arg2:T67	
R76	Overlap Arg1:T28 Arg2:T66	
R77	Has_Duration_or_Interval Arg1:T28 Arg2:T67	
T88	PROC 1751 1760	selección
#70	AnnotatorNotes T88	C0242802; Patient Selection; Research Activity
R78	Before Arg1:T31 Arg2:T88	
R79	Before Arg1:T28 Arg2:T88	
R80	Experiences Arg1:T68 Arg2:T32	
R81	Experiences Arg1:T68 Arg2:T33	
R82	Experiences Arg1:T68 Arg2:T34	
R83	Experiences Arg1:T68 Arg2:T35	
R84	Experiences Arg1:T68 Arg2:T36	
R86	Experiences Arg1:T53 Arg2:T82	
R87	Causes Arg1:T18 Arg2:T82	
T89	CONC 641 664	informe histopatológico
#71	AnnotatorNotes T89	C0807321; Pathology report; Intellectual Product
R23	Has_Quantifier_or_Qualifier Arg1:T18 Arg2:T80	
#72	AnnotatorNotes T83	C0162643; treatment failure; Finding
A20	Experiencer T61 Patient
A21	Experiencer T62 Patient
A22	Experiencer T64 Patient
A23	Experiencer T65 Patient
A24	Experiencer T68 Patient
A25	Experiencer T45 Patient
A26	Experiencer T48 Patient
A27	Experiencer T49 Patient
A28	Experiencer T51 Patient
A29	Experiencer T53 Patient
A30	Experiencer T56 Patient
A31	Experiencer T58 Patient
